CoChat

Withdrawing Benzodiazepines in Primary Care

The DOI matches its Crossref record; 101 of the 102 references it cites were found in a registry or an index.

Abstract

The use of benzodiazepine anxiolytics and hypnotics continues to excite controversy. Views differ from expert to expert and from country to country as to the extent of the problem, or even whether long-term benzodiazepine use actually constitutes a problem. The adverse effects of these drugs have been extensively documented and their effectiveness is being increasingly questioned. Discontinuation is usually beneficial as it is followed by improved psychomotor and cognitive functioning, particularly in the elderly. The potential for dependence and addiction have also become more apparent. The licensing of SSRIs for anxiety disorders has widened the prescribers' therapeutic choices (although this group of medications also have their own adverse effects). Melatonin agonists show promise in some forms of insomnia. Accordingly, it is now even more imperative that long-term benzodiazepine users be reviewed with respect to possible discontinuation. Strategies for discontinuation start with primary-care practitioners, who are still the main prescribers.This review sets out the stratagems that have been evaluated, concentrating on those of a pharmacological nature. Simple interventions include basic monitoring of repeat prescriptions and assessment by the doctor. Even a letter from the primary-care practitioner pointing out the continuing usage of benzodiazepines and questioning their need can result in reduction or cessation of use. Pharmacists also have a role to play in monitoring the use of benzodiazepines, although mobilizing their assistance is not yet routine. Such stratagems can avoid the use of specialist back-up services such as psychiatrists, home care, and addiction and alcohol misuse treatment facilities.Pharmacological interventions for benzodiazepine dependence have been reviewed in detail in a recent Cochrane review, but only eight studies proved adequate for analysis. Carbamazepine was the only drug that appeared to have any useful adjunctive properties for assisting in the discontinuation of benzodiazepines but the available data are insufficient for recommendations to be made regarding its use. Antidepressants can help if the patient is depressed before withdrawal or develops a depressive syndrome during withdrawal. The clearest strategy was to taper the medication; abrupt cessation can only be justified if a very serious adverse effect supervenes during treatment. No clear evidence suggests the optimum rate of tapering, and schedules vary from 4 weeks to several years. Our recommendation is to aim for withdrawal in <6 months, otherwise the withdrawal process can become the morbid focus of the patient's existence. Substitution of diazepam for another benzodiazepine can be helpful, at least logistically, as diazepam is available in a liquid formulation.Psychological interventions range from simple support through counselling to expert cognitive-behavioural therapy (CBT). Group therapy may be helpful as it at least provides support from other patients. The value of counselling is not established and it can be quite time consuming. CBT needs to be administered by fully trained and experienced personnel but seems effective, particularly in obviating relapse.The outcome of successful withdrawal is gratifying, both in terms of improved functioning and abstinence from the benzodiazepine usage. Economic benefits also ensue.Some of the principles of withdrawing benzodiazepines are listed. Antidepressants may be helpful, as may some symptomatic remedies. Care must be taken not to substitute one drug dependence problem for the original one.

Overview

Integrity signals

Registry

Crossref · 10.2165/0023210-200923010-00002

Cites

101 of 101 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 101 references

Research works printed but not linked: 18

  1. Priest, 1988, sychiatry, 12, 107
  2. Sorock, 1988, Arch Intern Med, 148, 2441, 10.1001/archinte.1988.00380110083017 · doi:10.1001/archinte.1988.00380110083017 · Paper page
  3. Deans, 1992, JRSoc Med, 85, 83
  4. Siriwardena, 2006, Br J Gen Pract, 56, 964
  5. Zandstra, 2002, Br J Gen Pract, 52, 805
  6. Hughes, 1997, J Clin Eff, 2, 79
  7. Bashir, 1994, Br J Gen Pract, 44, 408
  8. Cormack, 1994, Br J Gen Pract, 44, 5
  9. Towle, 2006, Pharm J, 276, 136
  10. Denis, 2006, Cochrane Database Syst Rev, &NA;, CD005194
  11. Lemoine, 1997, Encephale, 23, 290
  12. Rickels, 1986, Psychopharmacol Bull, 22, 407
  13. Busto, 1989, JClin Psychopharmacol, 9, 412
  14. Busto, 1998, JPsychiatry Neurosci, 23, 35
  15. Gerra, 1993, Curr Ther Res, 54, 580, 10.1016/S0011-393X(05)80679-4 · DOI
  16. Gilhooly, 1998, Br J Gen Pract, 48, 1601
  17. Baillargeon, 2003, Can Med Assoc J, 169, 1015
  18. Fletcher, 1995, Br J Gen Pract, 45, 467

Cited by

See all 318

Metadata

Authors
Lader, M., Tylee, A., & Donoghue, J.
Affiliations
  • King's College London (GB)
  • Liverpool John Moores University (GB)
Corresponding author
Lader, Malcolm
Venue
CNS Drugs
Published
2009
Volume
23
Issue
1
Pages
19-34
ISSN
1172-7047 (ISSN-L)
OpenAlex
W2015804212
Cited by
318
References
102
Citations by year
2026: 6 · 2025: 8 · 2024: 12 · 2023: 10 · 2022: 14 · 2021: 25 · 2020: 34 · 2019: 17 · 2018: 18 · 2017: 20 · 2016: 19 · 2015: 16 · 2014: 23 · 2013: 22 · 2012: 21
FWCI
1.48
Type
journal article
Language
en
Open access
closed
Locations
  • CNS Drugs (publishedVersion)
  • PubMed (publishedVersion)
  • Research Portal (King's College London) (submittedVersion)
Topics
  • Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords
benzodiazepine withdrawal, benzodiazepine discontinuation, benzodiazepine dependence, tapering, diazepam, carbamazepine, antidepressants, cognitive behavioral therapy, pharmacological interventions, primary care, prescribing monitoring, melatonin receptor agonists, selective serotonin reuptake inhibitors, insomnia, elderly patients
MeSH terms
Animals, Anxiety, Benzodiazepines, Humans, Primary Health Care, Psychotherapy, Substance Withdrawal Syndrome, Anti-Anxiety Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Withdrawing Benzodiazepines in Primary Care. https://app.cochat.ai/papers/10.2165/0023210-200923010-00002
The paper
Lader, M., Tylee, A., & Donoghue, J. (2009). Withdrawing Benzodiazepines in Primary Care. CNS Drugs. https://doi.org/10.2165/0023210-200923010-00002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.